#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Treatment of metastatic bladder cancer, systemic chemotherapy, symptomatic treatment


Authors: J. Katolická
Authors place of work: Onkologicko-chirurgické oddělení FN u svaté Anny v Brně
Published in the journal: Urol List 2012; 10(2): 54-56

Summary

Chemotherapy is the standard approach for inoperable locally advanced or metastatic cancer treatment. The recommended chemotherapeutical regime for the first line treatment includes gemcitabin/cisplatin, which has replaced M-VAC. Based on III phase study results we can recommend vinflunin for the second line treatment of urothelial cancer after cisplatin (as the first line regime) intolerance/failure.

Key words:
chemotherapy, cisplatin, gemcitabin, vinflunin


Zdroje

1. Sternberg CN, Yagoda A, Scher HI et al. Metho­trexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothe­lium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448–2458.

2. Loehrer PJ Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co­ope­rative group study. J Clin Oncol 1992; 10(7): 1066–1073.

3. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urotelial tumors. J Clin Oncol 1990; 8(6): 1050–1055.

4. Sternberg CN, de Mulder PH, Schornagel JH et al. Ran­domized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granu­locyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Orga­ni­zation for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 2001; 19(10): 2638–2646.

5. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatine versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068–3077.

6. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel//cisplatine/gemcitabine (PCG) and gemcitabine//cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. American Society of Clinical Oncology Annual Meeting 2007; Chicago, IL.

7. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatinwith granulocyte colony-stimulatingfactor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized phase III study from Helenic Cooperative Oncology Group. J Clin Oncol 2004; 22(2): 220–228.

8. Dreicer R, Manola J, Roth BJ et al. Phase III trial methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of urotelium. Cancer 2004; 100(8): 1639–1645.

9. Hahn NM, Stadler WM, Zon R et al. Mature results from Hoosier Oncology Group GU 04-75 phase II trial of cisplatin (C), gemcitabine (G) and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Socienty of Clinical Onco­logy Annual Meeting: 2010. Chicago, IL.

10. Hussain RS, Vaishampayan U, Du W et al. Combi­nation paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19(9): 2527–2533.

11. Bellmunt J, Theodore C, Demkov Z et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitio­nal cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27(27): 4454–4461.

12. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2¨nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of Urological Oncology (AUO) trial AB 20/99) Ann Oncol 2011; 22(2): 288–294

Štítky
Paediatric urologist Urology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#